Medina

This research investigates dry eye disease by evaluating the safety and effectiveness of a fixed-dose combination of lifitegrast and perfluorohexyloctane given twice daily. The study is a 4-week, randomized, double-masked, parallel-group, active-controlled, multicenter trial focusing on improving signs and symptoms of dry eye disease. Participants must have a history of dry eye disease in both eyes for at least six months and meet specific symptom and sign criteria at screening and baseline. Participants will be assigned to one of several groups receiving topical eye drops for four weeks: the fixed-dose combination of lifitegrast and perfluorohexyloctane, lifitegrast alone, perfluorohexyloctane alone, or a vehicle drop without active ingredients. Each treatment is administered as an eye drop twice daily. The study compares these treatments to assess their impact on dry eye disease. Throughout the study, participants will undergo assessments including corneal fluorescein staining to measure changes from baseline at day 29. They will be monitored for adherence and safety, with evaluations of visual acuity and ocular health. The total participation time is approximately four weeks, during which researchers will track changes in dry eye disease signs and symptoms to evaluate treatment effects.

The goal of this clinical trial is to evaluate the safety and efficacy of the DG1 spectacle lens for myopia progression control in children. * To assess if the DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.75D in cycloplegic spherical equivalent autorefraction refractive error compared to single-vision (SV) spectacles over the study period. * To assess if DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.3mm in axial elongation compared to SV over the study period. The clinical trial will compare DG1 spectacle lens to single vision spectacle lens. Participants will wear spectacle lenses and return for visits at regularly scheduled intervals through a 36-month follow up visit. All subjects who complete the 36-month visit will continue in the study for an additional 12 months for the rebound evaluation.

Dry eye disease (DED) is a common condition affecting people of working age and older, causing symptoms like dryness and burning in the eyes. This condition often leads to reduced tear production or increased tear evaporation, which can significantly impact quality of life and work ability. Researchers are evaluating the effect of Acoltremon 0.003% (TRYPTYR), a drug recently approved by the FDA that targets specific nerve receptors to stimulate tear production, to see if it improves patients' quality of life and ability to perform work tasks over one month. Participants in this phase 4 study will receive Acoltremon (TRYPTYR) to assess its impact on dry eye symptoms. The study lasts one month and includes three visits at eye care centers in Memphis, Pittsburg, and Minneapolis. Eligible adults aged 18 to 75 with a history of dry eye disease for at least six months and significant symptoms will be enrolled. The study focuses on those with abnormal tear production and quality of life scores indicating difficulty in work due to dry eyes. During the study, participants will have their eye dryness and quality of life assessed, including work ability, over 28 days. Researchers will measure changes in quality of life work scores from the start to the end of the study. Visual acuity, tear production tests, and symptom questionnaires will be used to monitor treatment effects and safety. Participants must be willing to stop contact lens use and certain medications during the study period.

Researchers are evaluating how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4% affects the quality of life in people with presbyopia, a condition that makes near vision difficult. This Phase 4, multi-center study aims to measure improvements in near vision symptoms using validated questionnaires like the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) and the Visual Quality of Life with Time Survey (VisQualT) after four weeks of treatment. Participants will be treated with Qlosi™ twice daily in both eyes. At the screening visit, each participant will receive a pair of distance-only glasses and have baseline vision and survey data collected at a follow-up dispense visit 1-2 weeks later. After confirmation of good distance vision with the glasses, participants will start the eye drop treatment. Four weeks after beginning treatment, they will return for an evaluation visit 4-6 hours after the day's dose. During the study, researchers will monitor participants' near vision quality and overall visual satisfaction using questionnaires and visual acuity tests. The initial eye examinations including slit-lamp biomicroscopy and indirect ophthalmoscopy occur during screening. Participants will be compensated after the evaluation visit and then exited from the study, which lasts approximately 5-6 weeks from screening to final assessment.

Researchers are evaluating the safety and effectiveness of VDPHL01, an oral investigational drug, in treating female patients with Androgenetic Alopecia (AGA), a genetic condition causing hair loss due to an excessive hair follicle response to hormones. This Phase 3, multi-center, double-blind study involves adult women aged 18 to 65 with mild to moderate AGA. The study aims to assess changes in hair counts and participants' evaluation of treatment benefit after 6 months. Participants will be randomly assigned to receive either VDPHL01 extended release tablets once daily or twice daily, or a placebo tablet. The study includes 11 visits over approximately 13 months: screening, baseline (day 1), weeks 2, months 1, 2, 4, 6, 8, 10, 12, and a final visit at month 13. During the study, participants must maintain consistent hair length, style, and color, and agree to have a micro dot tattoo placed on the scalp for photography and assessment. Throughout the trial, researchers will monitor hair growth through non-vellus target area hair counts and collect participants' feedback on treatment benefits at 6 months. The study involves multiple assessments including photography of the scalp, questionnaires, and general health evaluations. Safety and efficacy data will be collected until the final visit at month 13.